Integrative Obesity Care Approaches for Cardiometabolic Health

Integrative obesity and cardiometabolic care offers a comprehensive approach to tackle obesity and enhance cardiovascular health.

Abstract: Integrated Cardiometabolic Care and Obesity Medicine

In this educational post, I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, guide you through an integrated, first-person journey across modern cardiometabolic care, obesity medicine, insulin resistance, hepatic health, sleep, mental wellness, musculoskeletal function, osteoarthritis mechanics, and women’s health in perimenopause and menopause. I present the latest findings from leading researchers and landmark clinical trials using modern, evidence-based methods, and I explain how integrative chiropractic care fits into real-world treatment for patients aged 40 to 60 and beyond. I also detail our multidisciplinary care model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I collaborate closely with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), an internist with over 40 years of experience. Together, we combine medical oversight, functional medicine, chiropractic care, personal injury rehabilitation, and patient-centered coaching to improve body composition, reduce adiposity and its complications, preserve muscle mass, and elevate quality of life. Throughout, I explain the physiological underpinnings, why each intervention is used, and share clinical observations from my practice and educational platforms, including WellnessDoctorRX and my LinkedIn, to ensure the concepts are well developed and easy to apply.

A Multidisciplinary Model Of Care In El Paso: How We Integrate Medicine, Chiropractic, And Functional Rehabilitation

I practice at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas. My clinical pathway bridges chiropractic, advanced practice nursing, and functional medicine, and my credentials reflect that integration: DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. Our model is built around collaboration with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD, a Board-Certified Internist with over four decades of experience (NPI #1164426749; Texas MD License #J2933). This multidisciplinary setup is common in integrative and injury-care clinics, where an MD provides medical direction alongside a chiropractor to ensure safe, comprehensive, and coordinated care.

• Our team aligns care across:

• • Medical oversight and diagnostics (Dr. Cardenas)
  • Integrative chiropractic care, neuro-musculoskeletal rehabilitation, and movement optimization (Dr. Jimenez)
  • Functional medicine evaluation of root causes, nutrition, and lifestyle prescriptions (Dr. Jimenez)
  • Personal injury rehabilitation and case coordination
  • Health coaching, sleep and stress protocols, and behavior change support

• Why this structure matters:

• • It unifies structural, metabolic, and psychosocial domains
  • It reduces polypharmacy by combining conservative and medical therapies
  • It ensures measurement-driven decision-making and de-prescribing when appropriate
  • It improves adherence by resolving pain barriers and enabling movement

In this post, I integrate our cclinic’smodel with modern research to show how we approach obesity, insulin resistance, cardiometabolic risk, MASLD/MASH, obstructive sleep apnea (OSA), osteoarthritis, depression, stress physiology, and menopause. My goal is to make complex science readable, actionable, and empowering.

Framing Modern Obesity Care: Reducing Adiposity, Preserving Muscle, Elevating Quality Of Life

For years, the focus on the scale overshadowed what truly drives health outcomes. Today, contemporary obesity medicine emphasizes reducing harmful adiposity, especially visceral fat, while preserving or increasing lean muscle mass to protect metabolic rate, mobility, and functional independence. In my clinic, I emphasize sarcopenia-sparing strategies because indiscriminate weight loss can worsen metabolic health if muscle is lost.

• Our primary goals:

• • Reduce adiposity, especially visceral fat
  • Prevent and reverse obesity-related complications (type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, MASLD/MASH, sleep apnea, osteoarthritis)
  • Preserve and build lean muscle mass through adequate protein and resistance training
  • Improve quality of life: energy, sleep, mood, pain, mobility, and self-efficacy

• Why modest weight loss matters:
  • Even 5–10% total body weight reduction can produce clinically meaningful improvements:

• • • Prediabetes remission likelihood rises (ADA, 2024)
    • Type 2 diabetes markers improve, sometimes achieving remission with greater losses (Look AHEAD Research Group, 2013, 2014)
    • Dyslipidemia improves (triglycerides drop, HDL rises)
    • Blood pressure declines; antihypertensives can often be reduced under medical supervision
    • Sleep apnea and MASLD respond favorably around ~10% loss
    • Knee osteoarthritis pain decreases (lower joint forces)
    • Quality of life and mobility improve early, fueling adherence

This paradigm sets realistic targets and builds confidence. It helps patients recognize that health shifts begin with small, achievable steps, not perfection.

Cardiometabolic Syndrome Explained: The Double-Helix Of Obesity And Insulin Resistance

Cardiometabolic syndrome is a cluster of central adiposity, insulin resistance, dyslipidemia, and hypertension—a physiology that accelerates chronic disease. In my practice, I describe obesity and insulin resistance as a double helix: two intertwined strands amplifying each other.

• The endocrine reality of adipose tissue:

• • Visceral fat acts as an endocrine organ, secreting pro-inflammatory cytokines (TNF-α, IL-6) that impair insulin signaling (Hotamisligil, 2006).
  • Adipocyte hypertrophy increases lipolysis and free fatty acids (FFAs); ectopic lipid deposition in liver and muscle drives lipotoxicity and insulin resistance (Samuel & Shulman, 2016; Kim et al., 2019).
  • Chronic hyperinsulinemia sustains a storage-biased metabolism, promoting fat accretion and making weight loss harder (Cersosimo & DeFronzo, 2006).

• Clinical identification of cardiometabolic risk:

• • Increased waist circumference (men >102 cm; women >88 cm)
  • Elevated triglycerides (≥150 mg/dL)
  • Low HDL-C (men <40 mg/dL; women <50 mg/dL)
  • Elevated blood pressure (≥130/85 mmHg or on medication)
  • Elevated fasting glucose (≥100 mg/dL), dysglycemia, prediabetes, or diabetes

• Why this matters:

• • The presence of three or more criteria signals cardiometabolic syndrome and elevates risk for heart attack or stroke.
  • Early detection enables earlier, targeted intervention to break the double helix at biological and behavioral points.

In the clinic, I routinely calculate HOMA-IR and consider MetS-IR to index insulin resistance and cardiometabolic burden. These tools, paired with anthropometrics and advanced lipids like ApoB, sharpen risk stratification and guide intensity.

Building A Cardiovascular Risk Profile: Measurement-Driven Care

Under Dr. Cardenas’s medical direction, we assess risk comprehensively and pragmatically. Measurement strengthens clinical clarity and empowers patients with tangible milestones.

• Vital signs and anthropometrics:

• Blood pressure, height, weight, BMI, waist circumference
• Body composition: Bioelectrical Impedance Analysis (BIA) in-clinic; DEXA referrals when precise quantification is needed

• Laboratory evaluation:
  • Fasting lipid panel (Total-C, LDL-C, HDL-C, triglycerides)
  • Fasting glucose and A1c (glycemic status)
  • Advanced atherogenic markers:

• • • Apolipoprotein B (ApoB): counts total atherogenic particles more accurately than LDL-C
    • **Lipoprotein(a) [Lp(a)] : ** independent genetic risk factor for ASCVD

• Imaging and risk refinement:

• • Coronary Artery Calcium (CAC) scans for selected patients with multiple risk factors
  • Fib-4 and FibroScan for liver fibrosis staging (Angulo et al., 2007)

• Psychosocial evaluation:

• • Stress, depression (PHQ-9), anxiety (GAD-7), and social determinants of health that affect adherence and risk

This comprehensive profile makes cardiovascular prevention tangible and aligns our interventions with each patient’s biology and lived realities.

Obesity And The Heart: Epicardial Adipose Tissue, Hemodynamics, And Arrhythmias

Obesity harms cardiovascular health mechanically, inflammatorily, neurohormonally, and hemodynamically. Fat mass increases cardiac workload and blood volume. Epicardial adipose tissue (EAT) sits adjacent to myocardium and coronary arteries, exerting paracrine inflammatory effects that accelerate atherosclerosis, stiffen the heart (diastolic dysfunction), and increase arrhythmia risk.

• Key pathways:

• • Mechanical loading raises cardiac output and pressure
  • Chronic inflammation fosters plaque formation and instability
  • EAT’s proximity and shared blood supply intensify local vascular and electrical disturbances

• Clinical implications:

• • Treating obesity directly reduces EAT burden and improves both mechanical and inflammatory drivers of heart disease
  • Weight loss and cardiometabolic pharmacotherapy can improve symptoms, capacity, and events in obesity-related heart disease.

My experience echoes trial findings: when patients lose visceral fat and improve insulin signaling, their blood pressure stabilizes, exertional dyspnea declines, and quality of life improves.

Landmark Proof: The SELECT Trial And MACE Reduction With Semaglutide

For years, clinicians assumed treating obesity would reduce cardiovascular events, but we needed large-scale proof with modern medications. The SELECT trial provided that evidence.

• Study overview:

• • Participants: >17,600 adults ≥45 years old, BMI ≥27, established ASCVD, without diabetes
  • Intervention: Weekly semaglutide 2.4 mg vs. placebo plus standard cardiovascular care
  • Outcome: Time to first Major Adverse Cardiovascular Event (MACE)—CV death, non-fatal MI, or non-fatal stroke

• Result:

• • Semaglutide produced a ~20% relative risk reduction in MACE versus placebo

Clinical takeaway: Treating obesity is a potent cardiovascular prevention strategy, comparable in magnitude to high-intensity statins. In my practice, this reshapes conversations with high-risk patients—weight management is cardiovascular medicine.

Reference:

• SELECT trial findings are integrated within broader semaglutide evidence (Wilding et al., 2021; Rubino et al., 2022) and contemporary cardiometabolic literature.

Stage A Heart Failure: Prevention With A Four-Pillar Obesity Care Plan

Stage A heart failure describes patients at high risk due to obesity, hypertension, dyslipidemia, diabetes, or atherosclerosis, but without structural heart disease or symptoms. This is a window of opportunity.

• Our preventive pillars:
  • Nutrition therapy: DASH or Mediterranean patterns to lower blood pressure, refine lipids, and reduce inflammation
  • Physical activity: ≥150 minutes/week moderate-intensity aerobic plus resistance work to improve endothelial function, insulin sensitivity, and cardiac resiliency
  • Behavioral and sleep support: 7–8 hours/night sleep; stress reduction; adherence coaching
  • Medical/pharmacologic management:

• • • Optimize blood pressure, glycemia, and lipids under Dr. Cardenas’s oversight
    • Anti-obesity medications (AOMs) like semaglutide can achieve 10–15% weight loss and protect the heart via adiposity reduction

By loading the system with the right nutrition, movement, sleep, and pharmacology, we reduce cardiac workload and inflammatory tone, often averting progression.

Heart Failure With Preserved Ejection Fraction: STEP-HFpEF And SUMMIT Trials

HFpEF is notoriously challenging and tightly linked to obesity. Two trials changed the landscape.

• STEP-HFpEF:

• • Semaglutide 2.4 mg improved heart failure symptoms, exercise capacity, quality of life, and produced significant weight loss compared to placebo

• SUMMIT:

• • Tirzepatide, a dual GIP/GLP-1 agonist, reduced a composite of CV death or worsening heart failure events and improved symptoms and function compared to placebo

Clinical synthesis: Treating the underlying obesity in HFpEF treats the heart failure. In patients with obesity-related HFpEF, weight-loss pharmacotherapy plus lifestyle programs delivers functional and symptomatic gains that were elusive with prior approaches.

Dyslipidemia In Midlife: Atherogenic Patterns And ApoB

Insulin resistance reshapes lipoprotein metabolism: triglycerides rise, HDL drops, and small dense LDL particles proliferate. ApoB counts the atherogenic particles directly and often predicts risk better than LDL-C alone.

• Our approach:
  • Labs: fasting lipids, ApoB, Lp(a) when indicated
  • Risk tools: ASCVD Risk Calculator for 10-year risk; CAC scanning selectively
  • Interventions:

• • • Nutrition: Mediterranean-style low-fat, high-soluble fiber pattern to lower LDL and triglycerides
    • Exercise: ≥150 minutes/week moderate-intensity improves HDL and triglycerides
    • Pharmacotherapy: Statins plus anti-obesity medications for weight-driven lipid benefits

When patients reduce visceral fat and improve insulin signaling, triglycerides often normalize, HDL rises, and ApoB declines. In practice, I see synergy between statins and AOMs—lipids improve faster and more durably when weight loss is integrated.

Hypertension And Obesity: Renal Compression, RAAS, And Endothelial Dysfunction

Obesity drives up to 65–78% of essential hypertension, depending on sex. Mechanistically:

• Renal compression from visceral and retroperitoneal fat elevates intrarenal pressure, activates RAAS, and increases sodium retention and vasoconstriction
• Inflammation disrupts endothelial function, raising peripheral resistance
• Increased cardiac output from excessive mass elevates blood pressure
• Our protocol:

• • DASH diet, movement, and sleep optimization
  • Medical management of antihypertensives under Dr. Cardenas, with home BP monitoring and de-prescribing as weight loss lowers blood pressure.
  • Obesity pharmacotherapy selected for neutral or BP-lowering effects (GLP-1 class)

Patients frequently require fewer antihypertensives as they lose 10–15% of body weight; I caution them to measure BP at home to avoid hypotension during this transition.

Insulin Resistance: Central Mechanism, Lipotoxicity, And Hyperinsulinemia

Insulin resistance is the nexus between adiposity and cardiometabolic disease. Elevated FFAs deposit ectopically in liver and muscle, impairing insulin signaling. The pancreas compensates with hyperinsulinemia, which sustains a storage-dominant metabolism.

• Patient education is crucial:

• • I explain that they are fighting a hormonal headwind, not a personal failing
  • When patients understand biology, shame decreases and engagement increases
  • We target insulin demand through nutrition, sleep, stress reduction, movement, and—when indicated—pharmacotherapy

This shift from blame to biology is often the turning point in adherence and outcomes.

Early Detection Of Insulin Resistance: HOMA-IR, MetS-IR, And Annual Screening

Insulin resistance often precedes type 2 diabetes by 10–15 years (Tabák et al., 2009). Early detection saves beta-cell function and prevents downstream disease.

• Screening cadence:
  • Annual or semiannual labs in at-risk adults
  • Body weight, BMI, waist circumference, and blood pressure measured at each visit
  • Labs: fasting glucose, fasting insulin (HOMA-IR), A1c, lipid panel (TG, HDL, LDL), liver enzymes (ALT, AST), CMP, CBC; optional hs-CRP, ferritin, vitamin D
  • Indices:

• • • HOMA-IR for hepatic insulin resistance (Matthews et al., 1985)
    • MetS-IR as a cardiometabolic burden surrogate (Bello-Chavolla et al., 2018)
    • Fib-4 for liver fibrosis triage (Angulo et al., 2007)

• • Imaging:

• • • FibroScan for noninvasive staging when Fib-4 is indeterminate or high

My chiropractic assessment of movement and pain informs lab timing and exercise safety, ensuring we can escalate treatment with confidence.

References:

• Tabák, A. G., et al. (2009). Trajectories of glycemia before diabetes. The Lancet.
• Matthews, D. R., et al. (1985). HOMA method. Diabetologia.
• Bello-Chavolla, O. Y., et al. (2018). MetS-IR. International Journal of Obesity.
• Angulo, P., et al. (2007). Fibrosis-4 Index. Alimentary Pharmacology & Therapeutics.

Lower-Carbohydrate Nutrition: Reducing Insulin Demand And Stabilizing Glycemia

I often employ a lower-carbohydrate eating pattern to reduce insulin demand and enhance fat mobilization. This is not a moral stance against carbohydrates; it is a tailored tool for insulin resistance.

• Rationale:

• • Lower postprandial insulin exposure shifts metabolism toward lipolysis (Ludwig et al., 2018)
  • Hepatic insulin sensitivity improves; glycemic variability subsides (Hallberg et al., 2018)
  • Satiety rises with protein-forward meals; cravings diminish

• Practical features:

• • Non-starchy vegetables, fibrous carbs, lean proteins, healthy fats
  • Legumes, whole fruits, and minimally processed whole grains as tolerated
  • Protein 1.0–1.6 g/kg/day to preserve muscle, adjusted for age and activity
  • Mediterranean-influenced variants show cardiovascular protection (Schwingshackl & Hoffmann, 2014)

• Outcomes:

• • Better glycemic control, weight loss, triglyceride reduction (Gannon & Nuttall, 2004; Feinman et al., 2015)

We align nutrition with movement and chiropractic care to preserve lean mass and joint function, improving both compliance and long-term metabolic resilience.

References:

• Ludwig, D. S., et al. (2018). Low-carbohydrate diets and energy expenditure. BMJ.
• Hallberg, S. J., et al. (2018). Low-carb intervention in T2D. Diabetes Research and Clinical Practice.
• Schwingshackl, L., & Hoffmann, G. (2014). Mediterranean diet. AJCN.
• Gannon, M. C., & Nuttall, F. Q. (2004). High-protein diet in T2D. Diabetes.
• Feinman, R. D., et al. (2015). Low-carb diets and glycemic control. Nutrients.

Pharmacotherapy For Insulin Resistance And Obesity: Metformin, GLP-1, And Dual Agonists

Under Dr. Cardenas’s supervision, we consider pharmacotherapies when lifestyle is insufficient or risk is high.

• Metformin:

• • Mechanism: AMPK activation reduces hepatic gluconeogenesis and improves insulin sensitivity (Rena et al., 2017)
  • Role: Weight-neutral or modest weight loss; sometimes used off-label for insulin resistance in high-risk prediabetes
  • Evidence base: UKPDS showed benefits in overweight patients with T2D

• GLP-1 receptor agonists (e.g., semaglutide):

• • Mechanism: Enhances glucose-dependent insulin secretion, slows gastric emptying, reduces appetite (Nauck & Meier, 2018)
  • Evidence: Significant weight and A1c reductions; prediabetes reversion to normoglycemia in STEP (Wilding et al., 2021)

• Dual GIP/GLP-1 agonists (e.g., tirzepatide):

• • Mechanism: Synergistic incretin effects, robust weight loss, and A1c decline (Frias et al., 2021)
  • Evidence: SURMOUNT-1 showed dramatic weight loss and reduced progression to T2D in prediabetes cohorts (Jastreboff et al., 2022)

• Clinical practice considerations:

• • Selection based on ASCVD, CKD, HF, BMI, patient preferences, and access
  • We pair pharmacotherapy with resistance training and protein adequacy to prevent lean mass loss

Chiropractic and rehabilitation increase movement capacity, which synergizes with AOMs to protect metabolic flexibility and cardiorespiratory fitness.

References:

• Rena, G., et al. (2017). Metformin mechanisms. British Journal of Pharmacology.
• UKPDS Group. (1998). Metformin in overweight T2D. The Lancet.
• Nauck, M. A., & Meier, J. J. (2018). Incretins. NEJM.
• Frias, J. P., et al. (2021). Tirzepatide vs. semaglutide. NEJM.
• Jastreboff, A. M., et al. (2022). Tirzepatide in obesity. NEJM.
• Wilding, J. P. H., et al. (2021). Semaglutide in obesity. NEJM.

Cardiovascular Diabetology: Insulin Resistance Indices And Mortality Risk

Analyses leveraging NHANES data (2001–2018) reveal that surrogate indices of insulin resistance predict mortality, with MetS-IR showing strong associations with cardiovascular mortality in adults ≤65 years. In practice:

• I emphasize early detection of insulin resistance in midlife
• I use MetS-IR to stratify risk and escalate interventions
• I coordinate cardiology when indicated and intensify lifestyle and pharmacotherapy for high-risk profiles

This measurement-driven approach aligns with emerging literature and strengthens preventive cardiometabolic care.

Reference:

• Bello-Chavolla, O. Y., et al. (2018). MetS-IR. International Journal of Obesity.
• Contemporary NHANES-based IR-mortality analyses support risk stratification with IR indices.

Lessons From Look AHEAD: Lifestyle Works—And Integration Sustains It

The Look AHEAD trial offers durable insights into intensive lifestyle intervention in T2D:

• Findings:

• • Many achieved ~5% weight loss within 6 months; a subset maintained ≥10% over 8 years
  • Reduced medication needs, improved fitness, and quality of life
  • Weight loss corresponded to substantial glycemic improvements

• Practice implications:

• • Aim for ≥10% weight loss when feasible; maintain with structured follow-up
  • Stack interventions: nutrition, activity, pharmacotherapy, sleep, stress modulation
  • Integrative chiropractic care reduces pain barriers, improves proprioception, and accelerates movement goals

References:

• Look AHEAD Research Group. (2013). NEJM.
• Look AHEAD Research Group. (2014). JAMA.
• (2024). Standards of Medical Care in Diabetes.

Prediabetes And Obesity Pharmacotherapy: SURMOUNT-1 And STEP-10

When lifestyle is insufficient, modern pharmacotherapy can prevent diabetes progression.

• SURMOUNT-1 (tirzepatide):

• • ~94% reduction in progression to T2D at higher doses in prediabetes cohorts
  • Mean weight loss up to ~22.9% vs. placebo

• STEP-10 (semaglutide):

• • ~14% weight loss and ~81% reversion to normoglycemia in obesity with prediabetes settings

Clinical synthesis:

• In prediabetes with high BMI and comorbidities, pairing tirzepatide or semaglutide with structured nutrition and resistance training produces significant prevention and body composition benefits.

References:

• Jastreboff, A. M., et al. (2022). NEJM.
• Wilding, J. P. H., et al. (2021). NEJM.
• Rubino, D., et al. (2022). The Lancet Diabetes & Endocrinology.

MASLD And MASH: Updated Nomenclature, Pathophysiology, And Care Pathways

Terminology has evolved:

• MASLD: Metabolic dysfunction-associated steatotic liver disease
• MASH: Metabolic dysfunction-associated steatohepatitis
• Pathophysiology:

• • Insulin resistance increases de novo lipogenesis and FFA flux to the liver, fueling steatosis (Musso et al., 2010)
  • Inflammation and oxidative stress drive hepatocyte injury and fibrogenesis (Tilg & Moschen, 2010)

• Screening and triage:

• • Periodic ALT/AST in at-risk adults; ALT often > AST in MASLD
  • Fib-4 to stratify fibrosis risk; FibroScan for staging when indeterminate/high

• Treatment pillars:

• • Weight reduction target ~10% for steatosis and inflammation; ≥10% to improve histology in MASH (Vilar-Gomez et al., 2015)
  • Mediterranean low-carb variants; omega-3 emphasis
  • Resistance training reduces hepatic fat even without weight loss (Hallsworth et al., 2011)
  • Vitamin E in non-diabetic MASH with caution (Sanyal et al., 2010)
  • GLP-1/GIP agonists show promising liver benefits via weight loss (Newsome et al., 2021)
  • Resmetirom (THR-β agonist) is approved for MASH with F2–F3 fibrosis; coordinate hepatology (Harrison et al., 2023)

In practice, Dr. Cardenas oversees liver evaluations and pharmacology; I align rehabilitation and exercise prescriptions to protect hepatic physiology and avoid undue strain.

References:

• Eslam, M., et al. (2020). The Lancet.
• Musso, G., et al. (2010). Archives of Internal Medicine.
• Tilg, H., & Moschen, A. R. (2010). NEJM.
• Angulo, P., et al. (2007). APT.
• Vilar-Gomez, E., et al. (2015). Hepatology.
• Hallsworth, K., et al. (2011). Hepatology.
• Sanyal, A. J., et al. (2010). NEJM.
• Newsome, P. N., et al. (2021). NEJM.
• Harrison, S. A., et al. (2023). NEJM.

Stress, Depression, And Metabolism: Neuroendocrine Drivers And Clinical Tools

Metabolic disease is neuroendocrine and psychosocial, not merely caloric. Chronic stress elevates cortisol and catecholamines, increasing gluconeogenesis, visceral fat, and insulin resistance (Rosmond, 2005). Changes in brain circuitry impair self-regulation and bias hedonic eating (McEwen, 2007; Volkow et al., 2011).

• Clinical measures:

• • PHQ-9 for depression, GAD-7 for anxiety, PSS for stress
  • Sleep optimization is non-negotiable (7–8 hours/night)
  • Behavioral activation and mindful eating training

• Integrative chiropractic:

• • Manual therapy reduces nociceptive input and sympathetic arousal
  • Breathing training and proprioceptive work support parasympathetic tone and adherence

References:

• Rosmond, R. (2005). Journal of Internal Medicine.
• McEwen, B. S. (2007). Nature Reviews Neuroscience.
• Volkow, N. D., et al. (2011). Biological Psychiatry.
• Pratt, L. A., & Brody, D. J. (2014). NCHS Data Brief.

Eliminating Weight Bias: Psychological Safety As A Clinical Intervention

Bias undermines care. In my clinic, we use person-first language, shared decision-making, objective measurement, and validation.

• Why it matters:

• • Reduces care avoidance
  • Enhances alliance and adherence
  • Mitigates stress-driven cortisol elevations that sabotage progress

When patients feel respected and safe, they engage more deeply and sustain change. This is a therapeutic tool, not a courtesy.

Reference:

• Puhl, R. M., & Heuer, C. A. (2009). AJPH.

Musculoskeletal Health And Osteoarthritis: Load Mechanics And Metabolic Links

Osteoarthritis is biomechanical and metabolic (Berenbaum, 2013; Deveza & Loeser, 2018). Insulin resistance and adipocytokines fuel synovial inflammation and cartilage catabolism (Sellam & Berenbaum, 2013).

• Load mechanics:
  • Knee joint reactive forces scale with activity:

• • • Walking ~3× body weight
    • Stairs ~6× body weight
    • Jumping ~10× body weight

• Assessment:

• • Timed Up and Go, 30-second chair stand, grip strength, single-leg balance; targeted imaging

• Chiropractic and rehab strategies:

• • Joint adjustments for alignment and kinematics
  • Myofascial release for tissue glide and pain reduction
  • Neuromuscular control: hip abductors, core stability
  • Non-weight-bearing conditioning (swimming, cycling, aquatic therapy)
  • Progressive loading with cadence training and closed-chain strengthening

Weight reduction targets of 10–15% dramatically drop knee forces and pain. In practice, combining patellar tracking drills, hip abductor strengthening, anti-inflammatory diets, and weight loss yields marked improvements.

References:

• Berenbaum, F. (2013). Nature Reviews Rheumatology.
• Deveza, L. A., & Loeser, R. F. (2018). Nature Reviews Rheumatology.
• Sellam, J., & Berenbaum, F. (2013). Nature Reviews Rheumatology.

Obstructive Sleep Apnea: Fat Mass Disease, Airway Tone, And Metabolic Implications

Excess adiposity around the upper airway narrows and collapses the airway during sleep, fueling OSA, which worsens insulin resistance and weight gain (Peppard et al., 2000).

• Screening tools:

• • STOP-Bang and Epworth Sleepiness Scale
  • Polysomnography and AHI classification

• Treatment:

• • Weight reduction of 5–15%
  • CPAP adherence with mask refitting and coaching
  • Tirzepatide has received an FDA indication for OSA in people with obesity, reducing severity via weight loss mediation (SURMOUNT OSA program; 2024)

• Integrative care:

• • Chiropractic interventions reduce cervical/thoracic tension and improve posture
  • Diaphragmatic breathing and upper airway muscle endurance support sleep physiology

References:

• Peppard, P. E., et al. (2000). AJRCCM.
• FDA 2024 update for tirzepatide in OSA (press materials).

Pulling Evidence Together: Treating Obesity Improves Multiple Systems

Contemporary trials across cardiometabolic disease, HFpEF, OSA, osteoarthritis, and liver disease converge on a core principle: treat obesity to improve multi-system outcomes (Jastreboff et al., 2022; Wilding et al., 2021; Newsome et al., 2021; Harrison et al., 2023).

• Integrated gains:

• • Lower A1c and triglycerides; higher HDL
  • Reduced OSA severity and improved sleep architecture
  • Lower knee pain and higher functional capacity
  • Lower liver fat and improved fibrosis parameters with targeted agents

This validates our multidisciplinary approach: structural rehabilitation plus metabolic pharmacotherapy and behavior change create durable, system-wide benefits.

Case Integration: “Robert,” A 55-Year-Old Patient With Complex Cardiometabolic And Musculoskeletal Needs

Robert’s composite case reflects patients I serve. Identity details are altered for privacy. He presented with class III obesity, uncontrolled type 2 diabetes, dyslipidemia, hypertension, OSA, knee osteoarthritis, elevated waist circumference, elevated liver enzymes, and Stage A heart failure features. He reported fatigue, low libido, and CPAP intolerance.

• Initial medications:

• • Metformin 1000 mg BID
  • Glipizide 10 mg daily
  • Lisinopril 20 mg daily
  • Rosuvastatin 20 mg daily

• Goals:

• • ~20% weight loss
  • A1c < 7%
  • Improved sleep, mood, and musculoskeletal pain
  • Restored functional capacity

• Stepwise integrated plan:
  • Nutrition: Lower-carbohydrate Mediterranean pattern; protein 1.2–1.4 g/kg/day; plate method; cafeteria strategies; evening craving management
  • Physical activity: Non-weight-bearing cardio (bike, swimming); mobility; band-based strength; gradual closed-chain progression; pain threshold rules and safety monitoring
  • Integrative chiropractic care: Lumbopelvic and knee alignment; myofascial release; patellofemoral tracking; gait retraining; neuromuscular activation
  • Medical optimization (Dr. Cardenas):

• • • Maintain metformin; discontinue sulfonylurea; initiate tirzepatide with stepwise titration
    • Continue lisinopril and rosuvastatin with monitoring
    • CPAP adherence support; sleep medicine referral
    • Repeat ALT/AST at 3–6 months; Fib-4 reassessment; consider FibroScan or hepatology referral if indicated
    • Address mood with behavioral activation and counseling

• Three-year transformation:

• • Weight reduction: ~75 pounds (from 275 to ~200), BMI ~28.7
  • Waist circumference decline; improved BP
  • A1c stabilized in non-diabetic range
  • Triglycerides improved; quality of life and exercise tolerance enhanced

This case shows how combined medical direction, chiropractic rehabilitation, and modern pharmacotherapy produce durable, multi-dimensional outcomes.

Reversing Type 2 Diabetes: A First-Person Walkthrough Of Strategy, Titration, And Education

In complex T2D with obesity, I often replace hypoglycemia-prone, weight-promoting agents (e.g., sulfonylureas) with incretin-based therapies that reduce appetite and improve glycemia. I titrate carefully to minimize GI effects, and I align nutrition and resistance training to preserve muscle.

• Sexual dysfunction conversation:

• • I explain microvascular complications of long-standing hyperglycemia and hypertension
  • I address psychosocial impacts of obesity, stigma, and stress on libido
  • I connect root-cause treatment—weight loss, blood pressure control, sleep improvement—to sexual function improvements

Patient education reduces shame, strengthens alliance, and improves adherence to comprehensive care plans.

Menopause And Metabolic Health: Weight Gain, Central Adiposity, And Sarcopenia

Menopause is diagnosed after 12 consecutive months without menses, typically around 51 years old. Women may spend ~40% of life postmenopausal. Weight gain and central adiposity often increase during this transition, with muscle mass declining and bone resorption rising.

• Physiology:

• • Estrogen deficiency elevates LDL and total cholesterol, increases ghrelin and energy intake, reduces insulin sensitivity, and shifts fat distribution from gynoid to android (central) patterns
  • Muscle protein synthesis and bone protein synthesis become less efficient—partial anabolic resistance emerges

• Vasomotor symptoms (VMS):

• • Frequent, persistent VMS can precede weight gain; higher BMI and waist correlate with more severe VMS (Thurston et al., 2019)
  • Weight reduction decreases VMS severity

• Risks:

• • Cardiovascular disease risk rises 2–4-fold postmenopause
  • Insulin resistance increases; higher rates of prediabetes and T2D
  • Osteopenia, osteoporosis, anxiety, depression, sleep difficulties, genitourinary changes

• Treatment goals:

• • Prevent or minimize weight gain
  • Reduce visceral adiposity
  • Improve body composition (fat down, muscle preserved or up; bone stabilized)
  • Elevate physical and mental well-being
  • Reduce chronic disease risks
  • Improve quality of life

• Strategy:

• • Treat obesity first: stabilize weight, reduce insulin resistance, and improve body composition
  • Integrate nutrition, movement, sleep, stress management, and medical therapies (metformin, AOMs; consider MHT or non-hormonal VMS agents when appropriate)

References:

• Davis, S. R., et al. (2012). Climacteric.
• Lovejoy, J. C., et al. (2008). International Journal of Obesity.
• Thurston, R. C., et al. (2019). American Journal of Epidemiology.

Protein-Centric Nutrition For Women: Combating Anabolic Resistance And Sarcopenic Obesity

During perimenopause and postmenopause, many women require more protein to overcome anabolic resistance. I often recommend 1.2–1.8 g/kg of ideal body weight daily, spaced every 3–4 hours to consistently stimulate muscle protein synthesis. When whole-food intake is challenging, I use high-quality whey protein shakes, often fortified with vitamin D, to enhance muscle anabolic signaling.

• Why animal protein and leucine matter:

• • Complete amino acid profile; leucine triggers MPS
  • Regular dosing supports muscle maintenance and growth

• The double benefit:

• • Protein preserves muscle and bone
  • Protein increases satiety, reducing total energy intake naturally

References:

• Bauer, J. M., et al. (2013). Journal of the American Medical Directors Association.
• Paddon-Jones, D., et al. (2004). Experimental Gerontology.

Physical Activity Guidelines: Building A Resilient, Postmenopausal Body

I advocate structured movement plans with aerobic and resistance components.

• Guidelines:

• • Aerobic: 150–300 minutes/week moderate-intensity or 75–150 minutes/week vigorous intensity
  • Resistance: Two or more sessions per week covering all major muscle groups

• Stepwise approach:

• • Establish baseline
  • Set small, achievable goals
  • Celebrate progress
  • Gradually increase duration, frequency, or intensity.

Even if targets aren’t fully met, any movement improves metabolic health, bone density, and function. Chiropractic care supports alignment and neuromuscular control, making movement safer and more comfortable.

Sarcopenic Obesity: Recognizing And Treating The Hidden Phenotype

Sarcopenic obesity combines reduced muscle mass and strength with increased adiposity, creating a vicious cycle of functional decline and metabolic deterioration.

• Cycle:

• • Increased adiposity elevates inflammatory cytokines.
  • Inflammation and insulin resistance drive muscle catabolism and inhibit synthesis
  • Muscle loss reduces resting metabolic rate and activity capacity
  • Fat gain accelerates, amplifying inflammation

• Diagnosis:

• • Muscle function tests (grip strength, chair stand)
  • DEXA body composition analysis to quantify lean mass, fat mass, and visceral adipose tissue; BIA for in-clinic trend monitoring

• Prevalence and disparities:

• • ~16% overall; ~8% in adults 20–60; ~28% in older adults
  • Elevated in metabolic disease: ~20% in prediabetes; ~35% in T2D
  • High prevalence in certain groups (e.g., Mexican American women over 60)

• Treatment:

• • Nutrition: 1.0–1.5 g/kg ideal body weight protein; reduce ultra-processed carbs; emphasize fiber-rich vegetables and fruits
  • Exercise: Cardio plus resistance training twice weekly minimum
  • Physical therapy referrals for deconditioning and OA; chiropractic adjustments to optimize mechanics and reduce pain

References:

• Batsis, J. A., & Villareal, D. T. (2021). Nature Reviews Endocrinology.
• Bauer, J. M., et al. (2013). JAMDA.

Case Study: “Maggie,” 53-Year-Old With Perimenopause, Prediabetes, And Insulin Resistance

Maggie’s story is common: progressive weight gain during perimenopause, rising waist circumference, worsening lipids, and evolving prediabetes.

• Data highlights at age 53:

• • BMI increased from 22.6 to 27.5 over three years
  • Waist circumference crossed 35 inches
  • A1c rose to 5.8%; fasting glucose to 104 mg/dL
  • Fasting insulin elevated to 11.7 µU/mL
  • LDL-C 121 mg/dL; HDL-C declined to 54 mg/dL

• Diagnoses:

• • Overweight/early obesity with abdominal adiposity
  • Prediabetes with insulin resistance
  • Dyslipidemia
  • Well-controlled hypothyroidism

• Plan:
  • Nutrition: Reduce total carbohydrates; protein 90–100 g/day spaced every 3–4 hours; net carbs 50–100 g/day focusing on vegetables and fruit; reduce nightly wine to improve sleep and insulin sensitivity
  • Activity: Add 2–3 vigorous sessions weekly (incline walking, elliptical, cycling); begin resistance training once weekly, progressing to twice weekly
  • Medical:

• • • Metformin ER off-label for prediabetes, gentle titration starting at 500 mg with evening meal
    • Reassess gabapentin for VMS and insomnia; consider MHT for VMS and insulin resistance benefits
    • Improve sleep with CBT-I and hygiene coaching
    • Consider AOMs if lifestyle and metformin are insufficient

Maggie’s case shows how small, structured changes unlock metabolic improvements and preserve function in perimenopause.

Reference:

• Knowler, W. C., et al. (2002). NEJM.

Case Study: “Maria,” 59-Year-Old With Sarcopenic Obesity And Multiple Comorbidities

Maria presents with class II obesity, prior MI, uncontrolled T2D, MASLD, severe bilateral knee OA, and deconditioning.

• Initial profile:

• • BMI 35.7; waist 43.5 inches
  • A1c 7.4%; triglycerides 256 mg/dL; HDL-C 37 mg/dL
  • Elevated liver enzymes; on metformin, insulin, lisinopril, amlodipine, rosuvastatin, diclofenac

• DEXA confirms:

• • Body fat ~57.8%
  • Muscle mass ~4th percentile for peers
  • Visceral adipose tissue ~3.4 liters

• Plan:
  • Nutrition: Lower carbohydrates; high protein to address sarcopenia; anti-inflammatory emphasis
  • Strategic referrals: Physical therapy for sarcopenia, deconditioning, and OA; orthopedic surgery evaluation for injections or total knee replacement
  • Address bias: Advocate assertively to ensure Maria receives equitable surgical evaluation and comprehensive options
  • Medications:

• • • Initiate GLP-1 agonist (semaglutide) for weight loss and MACE reduction post-MI (Marso et al., 2016)
    • Taper off exogenous insulin as glycemia improves to enable weight loss

• • Activity:

• • • Adhere to PT exercises and begin resistance training 1–2 times per week
    • Prefer non-weight-bearing cardio: swimming, water aerobics, stationary cycling

Maria’s case underscores the importance of integrated medical oversight, aggressive metabolic therapy, mechanical rehabilitation, and advocacy to overcome structural and systemic barriers.

References:

• Marso, S. P., et al. (2016). NEJM.

Why Each Technique Is Used: Physiological Underpinnings And Rationale

I explain to patients how each intervention targets specific biological levers:

• Lower-carbohydrate nutrition:

• • Reduces insulin demand, stabilizes glycemic variability, and promotes lipolysis

• Resistance training:

• • Increases GLUT4 translocation; enhances insulin sensitivity; preserves lean mass; strengthens joint support

• Aerobic conditioning:

• • Improves mitochondrial function; increases fat oxidation; lowers resting heart rate and blood pressure

• Chiropractic adjustments:

• • Normalize joint kinematics; reduce nociception; relieve muscle guarding; improve movement economy

• Myofascial release:

• • Improves tissue glide and reduces pain signaling; increases range of motion

• Mindfulness and therapy:

• • Reduces stress reactivity; enhances executive control; sustains behavior change

• GLP-1/GIP agonists:

• • Suppress appetite; slow gastric emptying; restore incretin physiology; reduce weight and A1c

• CPAP:

• • Restores oxygenation and sleep architecture; reduces sympathetic surges; improves insulin sensitivity

Each intervention interlocks: better sleep reduces hunger hormones and insulin resistance; less pain increases movement; weight loss lowers joint forces and hepatic steatosis; improved glycemia reduces systemic inflammation.

Measurable Milestones And Follow-Up: Making Progress Visible

We set timelines and metrics to reinforce momentum:

• By 4 weeks:

• • Weight loss 2–4%
  • Fasting glucose down ~10–20 mg/dL
  • Reduced knee pain; improved sleep initiation

• By 12 weeks:

• • Weight loss 5–10%; A1c down 0.5–1.0%
  • Endurance increased 20–30%
  • BP improvement; CPAP adherence stabilized

• By 6 months:

• • Weight loss 10–15%; A1c <7% when baseline ~8.5%
  • Lipid improvements (TG down; HDL up)
  • ALT/AST normalization trend; Fib-4 re-evaluation

• By 12 months:

• • Maintain or advance to 15–20% weight loss
  • Sustained activity levels; low pain; enhanced quality of life

We anticipate plateaus; we respond by recalibrating macronutrients, periodizing training, optimizing pharmacotherapy, and intensifying behavioral strategies.

Clinical Observations From My Practice

From years of integrating movement, metabolic pharmacology, and chiropractic care:

• Patients receiving integrative chiropractic care achieve activity targets faster; pain barriers decrease, and movement confidence rises
• Protein-forward breakfasts reduce glycemic variability and hunger
• CPAP adherence produces early mood and energy improvements that catalyze exercise adherence
• Early wins (2–4% weight loss) in the first month predict long-term success—this is when coaching intensity should peak
• Knee OA pain responds best when patellar tracking drills, hip abductor strengthening, weight loss, and anti-inflammatory nutrition are combined

Explore more of my clinical perspectives and protocols at:

• WellnessDoctorRX: https://wellnessdoctorrx.com/
• LinkedIn: https://www.linkedin.com/in/dralexjimenez/

Educational Summary

This post consolidates modern evidence and practical strategies for detecting and treating insulin resistance, obesity, MASLD/MASH, depression, OSA, and osteoarthritis, while integratingwomen’ss health during perimenopause and menopause. Our care at Injury Medical Clinic PA blends medical oversight by Dr. Maria Guadalupe Cardenas, MD (Internal Medicine; NPI #1164426749; Texas MD License #J2933), with integrative chiropractic, functional medicine, and rehabilitation. Our approach is personalized, data-driven, and clinically pragmatic, designed to reduce adiposity, protect muscle, mitigate risks, and elevate quality of life.

References

• (2024). Standards of Medical Care in Diabetes—2024.
• Angulo, P., et al. (2007). The Fibrosis-4 Index identifies patients with advanced fibrosis in NAFLD. Alimentary Pharmacology & Therapeutics.
• Batsis, J. A., & Villareal, D. T. (2021). Sarcopenic obesity in older adults: etiology, epidemiology and treatment strategies. Nature Reviews Endocrinology.
• Bauer, J. M., et al. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: A PROT-AGE position paper. Journal of the American Medical Directors Association.
• Bello-Chavolla, O. Y., et al. (2018). Metabolic Syndrome-Insulin Resistance (MetS-IR) index. International Journal of Obesity.
• Berenbaum, F. (2013). Osteoarthritis: A disease of the whole joint. Nature Reviews Rheumatology.
• Cersosimo, E., & DeFronzo, R. A. (2006). Insulin resistance and obesity. Molecular Metabolism.
• Davis, S. R., et al. (2012). Understanding weight gain at menopause. Climacteric.
• Deveza, L. A., & Loeser, R. F. (2018). OA phenotypes and metabolic OA. Nature Reviews Rheumatology.
• Eslam, M., et al. (2020). MAFLD consensus-driven nomenclature for NAFLD. The Lancet.
• Feinman, R. D., et al. (2015). Low-carbohydrate diets and glycemic control. Nutrients.
• Frias, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in type 2 diabetes. NEJM.
• Gannon, M. C., & Nuttall, F. Q. (2004). High-protein, low-carbohydrate diet in type 2 diabetes. Diabetes.
• Hallberg, S. J., et al. (2018). Low-carb intervention in type 2 diabetes. Diabetes Research and Clinical Practice.
• Hallsworth, K., et al. (2011). Resistance exercise reduces liver fat in NAFLD. Hepatology.
• Harrison, S. A., et al. (2023). Resmetirom in NASH with F2–F3 fibrosis. NEJM.
• Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature.
• Jastreboff, A. M., et al. (2022). Tirzepatide for weight management in obesity. NEJM.
• Kim, J. A., et al. (2019). Insulin resistance in skeletal muscle and liver. Metabolism.
• Knowler, W. C., et al. (2002). Reduction in incidence of type 2 diabetes with lifestyle or metformin. NEJM.
• Look AHEAD Research Group. (2013). Long-term effects of lifestyle intervention. NEJM.
• Look AHEAD Research Group. (2014). Cardiovascular outcomes in Look AHEAD. JAMA.
• Lovejoy, J. C., et al. (2008). Increased visceral fat during menopausal transition. International Journal of Obesity.
• Ludwig, D. S., et al. (2018). Low-carbohydrate diets and energy expenditure. BMJ.
• Marso, S. P., et al. (2016). Semaglutide and cardiovascular outcomes in T2D. NEJM.
• Matthews, D. R., et al. (1985). HOMA method. Diabetologia.
• McEwen, B. S. (2007). Stress and the brain. Nature Reviews Neuroscience.
• Musso, G., et al. (2010). NAFLD and cardiovascular disease. Archives of Internal Medicine.
• Nauck, M. A., & Meier, J. J. (2018). Incretins and therapeutic implications. NEJM.
• Newsome, P. N., et al. (2021). Semaglutide in NASH. NEJM.
• Peppard, P. E., et al. (2000). Longitudinal study of OSA and weight gain. AJRCCM.
• Pratt, L. A., & Brody, D. J. (2014). Depression and obesity. NCHS Data Brief 167.
• Puhl, R. M., & Heuer, C. A. (2009). Obesity stigma and public health. AJPH.
• Rena, G., et al. (2017). Metformin mechanisms. British Journal of Pharmacology.
• Rosmond, R. (2005). Cortisol and insulin resistance. Journal of Internal Medicine.
• Rubino, D., et al. (2022). Semaglutide and cardiometabolic risk in obesity. The Lancet Diabetes & Endocrinology.
• Samuel, V. T., & Shulman, G. I. (2016). Mechanisms for insulin resistance. JCI.
• Sanyal, A. J., et al. (2010). Pioglitazone, vitamin E in NASH. NEJM.
• Schwingshackl, L., & Hoffmann, G. (2014). Mediterranean diet and cardiovascular risk. AJCN.
• Sellam, J., & Berenbaum, F. (2013). Metabolic syndrome and OA. Nature Reviews Rheumatology.
• Spiegel, K., et al. (2004). Leptin and ghrelin with sleep curtailment. JCEM.
• Tabák, A. G., et al. (2009). Trajectories of glycemia before diabetes. The Lancet.
• Tilg, H., & Moschen, A. R. (2010). Evolution of NAFLD. NEJM.
• UKPDS Group. (1998). Metformin in overweight patients with T2D. The Lancet.
• Vilar-Gomez, E., et al. (2015). Weight loss and NASH histology. Hepatology.
• Volkow, N. D., et al. (2011). Obesity and addiction neurobiology. Biological Psychiatry.
• Wilding, J. P. H., et al. (2021). STEP-1: Semaglutide in obesity. NEJM.

SEO tags: obesity care, cardiometabolic syndrome, insulin resistance, semaglutide, tirzepatide, GLP-1, GIP, HFpEF, SELECT trial, SUMMIT trial, DASH diet, Mediterranean diet, ApoB, Lp(a), coronary artery calcium, MASLD, MASH, resmetirom, sleep apnea, CPAP, osteoarthritis, knee pain, sarcopenic obesity, perimenopause, menopause, protein intake, resistance training, metformin, Look AHEAD, SURMOUNT-1, STEP-10, stress physiology, depression, weight bias, integrative chiropractic care, functional medicine, El Paso clinic, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC